Aminolevulinic acid hydrochloride is under clinical development by Photonamic and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aminolevulinic acid hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aminolevulinic acid hydrochloride overview
Aminolevulinic acid hydrochloride (Alacare/ Effala / Gliolan) is a radiation sensitizer used in photodynamic- radiation therapy. It is formulated as patch or plaster for topical and cutaneous application and powder for solution for oral route of administration. It is indicated for treatment of mild actinic keratoses lesions. It is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (gbm) on preoperative imaging, and who are intended for resection of the tumour.
Aminolevulinic acid hydrochloride is under development for the treatment of supratentorial IDH wild-type glioblastoma. The therapeutic candidate is administered through oral route. It is also under development for the treatment of distal subungual onychomycosis (DSO) of the great toenail. The therapeutic candidate is formulated as patch for topical administration.
Photonamic overview
Photonamic, a subsidiary of SBI ALApharma Co Limited, is a pharmaceutical company that develops 5-aminolevulinic acid (5-ALA) in various formulations as food supplements and cosmetics. The company’s 5-aminolevulinic acid is used in various therapeutic areas which include glioblastoma, local photodynamic therapy (PDT) and actinic keratosis. It sells its products under the brand name Gliolan and Alacar. Photonamic conducts research and development on 5-aminolevulinic acid (5-ALA) for both therapeutic and diagnostic approaches in the areas of oncology and dermatology. The company operates in Japan, the US, Germany and Canada, among others. Photonamic is headquartered in Pinneberg, Schleswig-Holstein, Germany.
For a complete picture of Aminolevulinic acid hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
